ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Inflammation"

  • Abstract Number: 1822 • ACR Convergence 2021

    Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies

    Peter C Taylor1, Andrew G Bushmakin2, Joseph C Cappelleri2, Pamela Young3, Rebecca Germino2, Joseph Merola4 and Gil Yosipovitch5, 1University of Oxford, Oxford, United Kingdom, 2Pfizer Inc, Groton, CT, 3Pfizer Inc, Collegeville, PA, 4Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 5University of Miami Miller School, Florida, FL

    Background/Purpose: Dermatologic symptoms of PsA can substantially impact patient (pt) health‑related quality of life (HRQoL);1 itch is the most commonly reported, and among the most…
  • Abstract Number: 0055 • ACR Convergence 2021

    Time Course of Intestinal Permeability and Intestinal Inflammation in Rat Adjuvant-induced Arthritis

    Sophie Hecquet1, Perle Totoson2, Marie-Paule Algros3, Hélène Martin2, Célian Peyronnel2, Maude Tournier2, Clement Prati1, Daniel Wendling1, Céline Demougeot2 and Frank Verhoeven1, 1Service de rhumatologie, CHU de Besançon, Besançon, France, 2PEPITE EA4267, FHU INCREASE, Bourgogne Franche-Comté University, Besançon, France, 3Service d'anatomopathologie, CHU de Besançon, Besançon, France

    Background/Purpose: Intestinal inflammation (I-Inf) and increased intestinal permeability (IP) and intestinal damage (ID) have been observed in patients with spondyloarthritis (SpA). However, whether these changes…
  • Abstract Number: 0511 • ACR Convergence 2021

    Tumor Necrosis Factor-α Modulates Endothelial-to-mesenchymal Transition and Increases Protein Tyrosine Phosphatase 1B

    Jorge Romo-Tena1, Jose Esparza-Lopez2, Carmelo Carmona-Rivera3, Luz P blanco3, Mariana Kaplan4 and María de Jesús Ibarra-Sánchez2, 1INNSZ / NIAMS, Mexico City, Mexico, 2INNSZ, Mexico City, Mexico, 3NIAMS, Bethesda, MD, 4National Institutes of Health, Bethesda, MD

    Background/Purpose: Endothelial dysfunction is a hallmark in the pathogenesis of many inflammatory diseases. The endothelial-to-mesenchymal transition (EndoMT) is a process where endothelial cells lose their…
  • Abstract Number: 1006 • ACR Convergence 2021

    MAA Modified and/or Citrullinated Proteins Stimulate Macrophages and Human Fibroblast-Like Synoviocytes to Increase the Secretion/Expression of Fractalkine Ligand (CX3CL1) and Fractalkine Receptor (CX3CR1)

    Nozima Aripova, Michael Duryee, Peter Maloley, Bryant England, James O'Dell, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: In rheumatoid arthritis (RA) synovium, activated synovial fibroblasts and macrophages release inflammatory mediators that affect surrounding cells and accelerate disease progression. One such chemokine…
  • Abstract Number: 1439 • ACR Convergence 2021

    Inhibitors of Endogenous Reverse Transcriptases Suppress in Vitro Type I Interferon Responses and in Vivo Antigen-specific T Cell Responses

    Nafeeza Hafeez, Jimmy Zhong, Jared Steranka, Margit Hagel, Greg Bisacchi, Donna Romero, Rosana Kapeller, Dennis Zaller and Wenyan Miao, Rome Therapeutics, Cambridge, MA

    Background/Purpose: Transposable elements (TEs) are mobile DNA elements that can replicate and move from one position to another within the host genome. Through co-evolution, TEs…
  • Abstract Number: 1835 • ACR Convergence 2021

    Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies

    Joseph Merola1, Iain McInnes2, Atul Deodhar3, Erhard Quebe-Fehling4, Maher Aassi4, Michael Peine4 and Nehal Mehta5, 1Department of Dermatology and Department of Medicine, Division of Rheumatology; Brigham and Women's Hospital, Harvard Medical School, Newton, MA, 2University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, 3Oregon Health & Science University, Portland, OR, 4Novartis Pharma AG, Basel, Switzerland, 5NHLBI/National Institutes of Health, Bethesda, MD

    Background/Purpose: Psoriasis (PsO), Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (AxSpA) are chronic immune-mediated inflammatory diseases (IMIDs) requiring long-term treatment. Systemic inflammation in these IMIDs is…
  • Abstract Number: 0084 • ACR Convergence 2021

    COVID-19 Pneumonia in Two Hospitals: Similar Outcomes Despite Differential Use of Tocilizumab

    Leanna Wise1, Lauren Mathias2, Wendy Mack2, Aarya Kafi3, Yash Kothari2, Omkar Rao3 and William Stohl4, 1LAC+USC/Keck Medicine of USC, Pasadena, CA, 2University of Southern California, Los Angeles, CA, 3University of California San Diego, San Diego, CA, 4University of Southern California Keck School of Medicine, Los Angeles, CA

    Background/Purpose: A substantial number of patients with COVID-19 pneumonia develop a hyperinflammatory state. The anti-IL-6 receptor (IL-6R) mAb tocilizumab (TCZ) has been used in such…
  • Abstract Number: 0527 • ACR Convergence 2021

    Role of Terminal Uridylyl Transferase 7 in TNF-α-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts In Vitro

    Anil singh, farheen Shaikh and Salah-uddin Ahmed, Washington State University, Spokane, WA

    Background/Purpose: Terminal uridylyl transferase 7 (TUT7), also known as Zcchc6, is a zinc finger domain-containing protein responsible for terminal uridylation of miRNA, implicated in pre-miRNA…
  • Abstract Number: 1013 • ACR Convergence 2021

    SARS-CoV-2 Antibody Phenotype and Immune Gene Expression in Multi-system Inflammatory Syndrome in Children

    Kate Webb1, Thandeka Moyo-Gwete2, Simon Mendelsohn3, Claire Butters4, Simone Richardson5, Heidi Facey-Thomas4, Debbie Abrahams4, Mashudu Madzivhandila5, Zanele Makhado5, Frances Ayres5, William Horsnell6, Neilia Manamela5, Richard Baguma3, Stanley Kimbung Mbandi3, Mzwandile Erasmus3, Thomas Scriba3, Liesl Zühlke7, Penny Moore5, George Kassiotis8 and Christiaan Scott4, 1Paediatric Rheumatology University of Cape Town/ Francis Crick Institute, Cape Town, South Africa, 2National Institute of Communicable Diseases/University of Witwatersrand, Johannesburg, South Africa, 3South African TB vaccine initiative, IIDM, University of Cape Town, Cape Town, South Africa, 4Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, 5National Institute of Communicable Diseases/University of Witwatersrand, Cape Town, South Africa, 6University of Cape Town, Cape Town, South Africa, 7Paediatric Cardiology, University of Cape Town, Cape Town, South Africa, 8Retroviral Immunology, Francis Crick Institute, London, United Kingdom

    Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a severe disease that affects a small proportion of children exposed to Severe Acute Respiratory Syndrome Coronavirus…
  • Abstract Number: 1441 • ACR Convergence 2021

    Pharmacological Characterization of GLPG3667, a Selective TYK2 Inhibitor for Treatment of Inflammatory Diseases

    Roland Blanque1, Kenji Shoji1, Mia Jans2, Florence Marsais1, Laetitia Furio1, Maikel Colli2, Céline Cottereaux1, Christelle David1, Nicolas Houvenaghel2, Isabelle Parent1, An Van de Water2, Laetitia Perret1, Sofia Alves1, David Amantini1, Steven Van der Plas3 and René Galien4, 1Galapagos SASU, Romainville, France, 2Galapagos NV, Mechelen, Belgium, 3Formally Galapagos NV, Mechelen, Belgium, 4Galapagos NV, Romainvulle, France

    Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates the signaling from type 1 interferon (IFN), interleukin (IL)-12/IL-23 and the IL-10 family of…
  • Abstract Number: 1920 • ACR Convergence 2021

    Association of C-reactive Protein and Non-Steroidal Anti-inflammatory Drugs with Cardiovascular Events in Patients with Psoriatic Arthritis: A Time-dependent Cox Regression Analysis

    Ho Man Lam1, Ho So2, Isaac Cheng1, Edmund Li1, Priscilla Wong3, Tena Li1, Alex Lee1 and Lai-Shan Tam4, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2CUHK, Hong Kong, China, 3Prince of Wales Hospital, Hong Kong, Hong Kong, 4Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)

    Background/Purpose: Psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to underlying inflammation. Whether inflammatory burden and drugs used to suppress inflammation over time are…
  • Abstract Number: 0090 • ACR Convergence 2021

    Subcutaneous Sarilumab in Hospitalized Patients with Moderate-severe COVID-19 Infection Compared to the Standard Care: An Open-label Randomized Clinical Trial

    Sebastián C Rodriguez-García1, Isidoro Gonzalez-Alvaro1, Francisco Abad-Santos2, Azucena Bautista-Hernández3, Lucio García-Fraile3, Juan Pablo Baldivieso-Achá4, Jesús Sanz-Sanz3 and Rosario Garcia de Vicuña1, 1Rheumatology Service. La Princesa University Hospital, Madrid, Spain, 2Clinical Pharmacology Service. Clinical Research and Clinical Trials Unit. La Princesa University Hospital, Madrid, Spain, 3Division of Infectious Diseases, Internal Medicine Service. La Princesa University Hospital, Madrid, Spain, 4Rheumatology Department. La Princesa University Hospital, Madrid, Spain

    Background/Purpose: Many uncertainties remain for IL-6 blockers on the management of COVID-19 such as the optimal time of intervention, the schedule of administration and predictors…
  • Abstract Number: 0541 • ACR Convergence 2021

    N-formyl Methionine Peptide-mediated Neutrophil Activation in Systemic Sclerosis

    Runa Kuley1, Ryan Stultz2, Bhargavi Duvvuri2, Roger Hesselstrand3, J Lee Nelson4 and Christian Lood2, 1Division of Rheumatology, University of Washington, Seattle, WA, 2University of Washington, Seattle, WA, 3Lund University, Lund, Sweden, 4Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

    Background/Purpose: Systemic sclerosis (SSc) is a complex systemic autoimmune disease, and its etiology is unknown. Exaggerated neutrophil activation and formation of neutrophil extracellular traps (NETs)…
  • Abstract Number: 1016 • ACR Convergence 2021

    Assessment of Pre-Inflammatory Mesenchymal (PRIME) Cells as a Biomarker of Tumor Necrosis Factor-Induced Arthritis in Mice

    Kiana Chen1, Xi Lin1, Lianping Xing2, H. Mark Kenney3, Richard Bell4, Edward Schwarz5 and Homaira Rahimi5, 1University of Rochester School of Medicine and Dentistry, Rochester, NY, 2University of Rochester Medical Center, Webster, NY, 3University of Rochester Medical Center, Rochester, NY, 4Hospital for Special Surgery, New York, NY, 5University of Rochester, Rochester, NY

    Background/Purpose: Recently, CD45−CD31−Podoplanin (PDPN)+ synovial fibroblast-like cells, termed pre-inflammatory mesenchymal (PRIME) cells were found to be differentially expressed and circulate in the blood of rheumatoid…
  • Abstract Number: 1454 • ACR Convergence 2021

    RHAPSODY: Rilonacept, an IL-1α and IL-1β Trap, Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a Phase 3 Trial of Patients with Recurrent Pericarditis

    Allan Klein1, Massimo Imazio2, Paul Cremer1, Antonio Brucato3, Antonio Abbate4, Fang Fang5, Antonella Insalaco6, Martin LeWinter7, Basil S. Lewis8, David Lin9, Sushil A. Luis10, Stephen J. Nicholls11, Arian Pano5, Alistair Wheeler12, Liangxing Zou5 and John F Paolini5, 1Department of Cardiovascular Imaging, Center for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, 2University Cardiology, Cardiovascular and Thoracic Department, AOU Città della Salute e della Scienza di Torino, Torino, Italy, 3Department of Biomedical and Clinical Science, University of Milano, Fatebenefratelli Hospital, Milan, Italy, 4VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, 5Kiniksa Pharmaceuticals Corp., Lexington, MA, 6Department of Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children's Hospital, Rome, Italy, 7Cardiology Unit, The University of Vermont Medical Center, The University of Vermont, Burlington, VT, 8Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center, Haifa, Israel, 9Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, 10Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, NY, 11MonashHeart, Department of Cardiology, Monash University, Clayton, Australia, 12Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda

    Background/Purpose: Recurrent pericarditis (RP) is an autoinflammatory disease with no FDA-approved therapies. RHAPSODY, a global Phase 3 study, evaluated rilonacept, a once-weekly IL-1α/IL-1β trap, in…
  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 58
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology